{"id":"NCT01302964","sponsor":"Massachusetts General Hospital","briefTitle":"Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders","officialTitle":"Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08","primaryCompletion":"2017-10-10","completion":"2017-10-10","firstPosted":"2011-02-24","resultsPosted":"2018-11-07","lastUpdate":"2018-11-07"},"enrollment":30,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Autism Spectrum Disorders"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":["Sugar pill"]},{"type":"DRUG","name":"Mirtazapine","otherNames":["Remeron"]}],"arms":[{"label":"Mirtazapine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will determine the effectiveness of mirtazapine in reducing anxiety in children with autistic disorder, Asperger's disorder and Pervasive Developmental Disorder.","primaryOutcome":{"measure":"Mean 10-Week Change in Pediatric Anxiety Rating Scale 5-Item Total Score, Double-blind Phase","timeFrame":"Weeks Baseline, 2, 4, 6, and 10","effectByArm":[{"arm":"Mirtazapine","deltaMin":-4.9,"sd":null},{"arm":"Placebo","deltaMin":-3.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":["35241779"],"seeAlso":["http://www.massgeneral.org/children/services/lurie-center/research.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":["Sedation/Drowsiness","Appetite increase","Irritability","Nausea","Stomach or abdominal discomfort"]}}